Loading
Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.
Linperlisib (YY-20394) was developed by Shanghai Yingli Pharmaceutical. The NMPA gave it conditional approval in November 2022 for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, on a single-arm phase 2 trial with an overall response rate near 80 percent. It is the first PI3K inhibitor developed in China to reach approval.
Blocks the delta form of PI3K, a signalling enzyme B-cell lymphomas depend on for survival.
1.Linperlisib slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2022 | Relapsed or refractory follicular lymphoma after two or more lines, conditional |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Linperlisib" OR ABSTRACT:"Linperlisib" OR TITLE:"YY-20394" OR ABSTRACT:"YY-20394" OR TITLE:"Yinlijia" OR ABSTRACT:"Yinlijia") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Linperlisib, not a curated reading list.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.